NCT06863220View on ClinicalTrials.gov

Intravesical Ozone Therapy for Interstitial Cystitis/Bladder Pain Syndrome

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

June 1, 2026

Conditions
Interstitial CystitisBladder Pain Syndrome
Interventions
OTHER

Intravesical Ozone Therapy

Patients received 50 mL ozonated saline (20-40 µg/mL) intravesically twice weekly for 3 weeks.

OTHER

Placebo (Normal Saline)

Patients received 50 mL normal saline intravesically twice weekly for 3 weeks.

OTHER

Control

Patients continued standard care (e.g., oral pentosan polysulfate) without intravesical intervention.

Trial Locations (1)

Unknown

İstanbul Başakşehir Çam Ve Sakura Şehir Hastanesi, Istanbul

All Listed Sponsors
lead

Medipol University

OTHER

NCT06863220 - Intravesical Ozone Therapy for Interstitial Cystitis/Bladder Pain Syndrome | Biotech Hunter | Biotech Hunter